301089 拓新药业
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-0.710-4.588-1.26016.31623.166
总资产报酬率 ROA (%)-0.634-4.070-1.10613.20217.704
投入资产回报率 ROIC (%)-0.689-4.457-1.22215.15020.536

边际利润分析
销售毛利率 (%)24.35326.37729.86757.87660.114
营业利润率 (%)-14.516-18.966-5.62438.50241.963
息税前利润/营业总收入 (%)-14.020-19.113-7.38837.48341.080
净利润/营业总收入 (%)-11.362-18.412-4.71529.09336.514

收益指标分析
经营活动净收益/利润总额(%)82.37877.96282.829100.57397.553
价值变动净收益/利润总额(%)-5.618-5.895-5.6002.2481.775
营业外收支净额/利润总额(%)0.2400.86814.475-1.627-1.236

偿债能力分析
流动比率 (X)4.1074.0074.0954.2272.392
速动比率 (X)2.7182.7633.0133.1771.823
资产负债率 (%)10.66510.87611.70112.81825.329
带息债务/全部投入资本 (%)0.6770.6620.2080.7538.550
股东权益/带息债务 (%)14,338.12514,658.02746,823.94112,857.6911,037.226
股东权益/负债合计 (%)837.666819.445754.662680.152294.798
利息保障倍数 (X)-26.394-975.4059.108-93.138-110.789

营运能力分析
应收账款周转天数 (天)50.61965.26498.28941.73522.814
存货周转天数 (天)243.025232.955233.101227.715234.763